Universal Biosensors Aktie
| 0,01AUD | 0,00AUD | 0,00% |
WKN DE: A0Q35S / ISIN: AU000000UBI2
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 60 | 81 | 83 | 80 | 76 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,05 | 0,07 | 0,05 | 0,08 | 0,08 |
Bilanz (in Mio. AUD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 31 | 25 | 37 | 22 | 18 |
| Summe Anlagevermögen | 26 | 20 | 10 | 8 | 8 |
| Summe Aktiva | 57 | 45 | 46 | 30 | 26 |
Bilanz (in Mio. AUD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 19 | 17 | 20 | 11 | 9 |
| Summe Eigenkapital | 38 | 28 | 26 | 20 | 17 |
| Summe Passiva | 57 | 45 | 46 | 30 | 26 |
Adresse
| 1 Corporate Avenue, 3178 Rowville | |
| Telefon | +61 (3) 9213-9000 |
| Fax | +61 (3) 9213-9099 |
| Internet | http://www.universalbiosensors.com |
Management
|
Ann Chew
Head-People, Strategy & Culture |
|
Anthony Soha
Head-Sales |
|
David L. Hoey
Independent Non-Executive Director |
|
Graham Mclean
Non-Executive Chairman |
|
Judith Ann Smith
Independent Non-Executive Director |
|
Keith Sims
Director-Global Marketing |
|
Luke Cossins
Chief Technology Officer |
|
Nicholas Bliesner
Head-Operations |
|
Peter Mullin
CEO, CFO, Managing Director, Secretary & Director |